Cranes now dominate the skyline at Grange Castle, where Pfizer is pouring more money into a single Irish site than it ever has before. Three and a half years after the company announced plans to more than double its biological drug substance capacity here, 2026 has brought a very different kind of milestone: fresh-faced apprentices walking through the gates to start careers that simply didn't exist at the site a generation ago, followed later in the year by a second wave of apprenticeship places as the build itself edges closer to the finish line.
A €1.2 billion bet on Dublin biologics
Grange Castle is no small operation to begin with. The 90-acre biotechnology campus in south-west Dublin already ranks among the largest integrated biotech manufacturing sites in the world, employing around 2,000 people across more than a million square feet of buildings and laboratories.
Then, in December 2022, Pfizer raised the stakes further, confirming it would invest more than €1.2 billion in a new manufacturing facility on the existing site to double its capacity for the biologics used to treat arthritis, cancer and inflammatory disease. By the company's own account, it is the biggest single pharmaceutical investment in the history of the Irish state, with 400 to 500 new roles expected once it is up and running.
The plan was always to move from preliminary design into onsite construction from 2024, with completion targeted for 2027. Environmental licensing documents filed with the Environmental Protection Agency in 2024 for the site's Ds2 project spell out just how sprawling that build-out is, covering everything from new production processes to sustainability and water stewardship measures as work has progressed.
Grange Castle sits within Grange Castle Business Park in Clondalkin, a location Pfizer chose decades ago precisely because it left room to keep growing. The new biologics building being added under the Ds2 project is designed to stand alongside, rather than replace, the site's existing production trains, so once the project is handed over the campus will run old and new capacity side by side rather than switching from one to the other.
Why Grange Castle matters to Pfizer's pipeline
None of this is happening in isolation. The new facility is being built to support Pfizer's growing pipeline in oncology, rare disease, inflammation and immunology, and internal medicines, giving the company extra headroom for products already on the market as well as ones still working their way through development.
Grange Castle already produces some of Pfizer's most widely used biologics and vaccines, and it sits alongside the company's other Irish plants in Newbridge, Co Kildare, and Ringaskiddy, Co Cork, which together turn out medicines used to treat arthritis, cancer, haemophilia, pain and stroke. Pfizer says it has invested around $8 billion in its Irish operations since opening its first site here in 1969, and today employs roughly 3,700 people across six locations.
That network gives Grange Castle a very specific job: it is where Pfizer wants large-scale biologics capacity, rather than the small-molecule or fill-finish work handled elsewhere in the country. Doubling biological drug substance output at a single site is a fundamentally different challenge to building a facility from scratch, since every step has to be designed around a plant that keeps running while the new building rises around it.
The 2026 apprenticeship pipeline
While the new manufacturing building continues to climb, Pfizer has also been investing in the people who will eventually run it. In March 2026 the company launched its latest Apprenticeship Programme at Grange Castle, putting 14 of the 22 apprenticeships available across its Irish sites at the Dublin campus alone.
Delivered through Ireland's National Apprenticeship Programme in partnership with SOLAS, the roles span quality control laboratory work, logistics, and manufacturing engineering, with structured pathways lasting two to four years that combine paid, on-the-job learning with recognised QQI qualifications. A QC Laboratory apprenticeship leads to a Level 7 science qualification, while manufacturing engineering apprentices can qualify at Level 7 in maintenance or core engineering, giving school leavers and career changers alike a route into the plant without needing a college degree first.
Pfizer frames the scheme as open to people of all ages and backgrounds, a deliberate widening of the traditional route into pharma manufacturing careers at a site that will need a steady supply of skilled engineers and scientists as its new biologics facility comes on stream.
Tracy Walshe, site lead at Pfizer Grange Castle, said the 2026 programme reflects the site's ambition to build homegrown talent for the years ahead [4](https://www.dublinlive.ie/news/dublin-news/pfizer-announces-22-apprenticeships-dublin-33540615). Applications for that March intake closed on 17 March 2026, with roles including a three-year QC Laboratory apprenticeship run jointly with Newbridge and leading to a QQI Level 7 science qualification, and a two-year logistics apprenticeship leading to a Level 6 qualification in supply chain and logistics [3](https://www.madein.ie/content/news/pfizer-launches-2026-apprenticeship-programmes-in-ireland).
Pfizer didn't stop there. In May 2026 the company opened a further Process Technician Apprenticeship at Grange Castle, a two-year earn-and-learn programme delivered with IBEC and TU Dublin leading to a Higher Certificate, or QQI Level 6, in Bio Process and Chemical Process Technology, with apprentices starting in September 2026 [2](https://www.linkedin.com/posts/adammoconnor_apprenticeship-earlycareers-processtechnician-activity-7457368491525058560-q5xv). Running a laboratory apprenticeship alongside the process technician track, plus a separate three-year Laboratory Apprenticeship delivered with Technology University Dublin's Tallaght campus, shows Pfizer building several distinct entry routes into the site rather than a single scheme [1](https://www.pfizer.com/about/careers/job/4951044).
How the wider build is tracking
With completion still pencilled in for 2027, Grange Castle is now deep into its construction and commissioning phase, exactly the point where a project like this generates the most construction jobs and lays the groundwork for the specialist roles that follow. The apprenticeship intake and ongoing recruitment for engineering and quality roles suggest Pfizer is already building the workforce it will need to run the expanded plant once the new building is handed over.
For the local economy around Clondalkin and south-west Dublin, that means a multi-year pipeline of construction activity now, followed by thousands of permanent, well-paid manufacturing and laboratory jobs once the facility is fully operational, on top of the roughly 5,500 total Pfizer roles the investment was expected to support in Ireland.
The 22 apprenticeships spread across Dublin, Kildare and Cork in 2026 also included longer four-year craft apprenticeships in mechanical automation and maintenance fitting, and in electrical instrumentation, based at Ringaskiddy and Newbridge [3](https://www.madein.ie/content/news/pfizer-launches-2026-apprenticeship-programmes-in-ireland). That spread across sites and disciplines suggests Pfizer treats skills investment as a company-wide priority in Ireland, not something confined to whichever site happens to be mid-build, which should smooth the eventual handover of Grange Castle's new building to operations.
Pfizer's environmental filings for the Ds2 project also detail sustainability commitments running alongside the build, including measures to manage construction-phase water use and to improve long-term energy efficiency in the new facility's design, part of a broader push across Pfizer's global manufacturing network to add biologics capacity that costs less to run over its lifetime. For a campus that already houses more than a million square feet of laboratories and production halls, adding a further large-scale building without disrupting existing output has demanded careful sequencing between construction crews and the teams keeping current biologics production running, a balancing act that has shaped much of the project's timeline since ground was broken.
The apprenticeship intake is also timed with an eye on the calendar: a three or four-year programme started in 2026 should produce qualified engineers and laboratory technicians at roughly the point the new biologics building moves from commissioning into full commercial production, giving Pfizer a pipeline of site-trained staff arriving just when the expanded plant is likely to need them most.
The Bottom Line
Pfizer's Grange Castle expansion is on course, with the biggest pharmaceutical investment in Irish history moving from blueprints to steel and concrete ahead of its 2027 completion date. Just as tellingly, the company is using 2026 to open new doors into the industry through apprenticeships, giving people without a traditional science degree a paid, qualification-earning way into one of Dublin's biggest biotech employers, right as it prepares to double its biologics capacity.
Health Pulse — Ireland's home for health and healthcare intelligence. Subscribe to the Pulse Network Briefing.